LIAN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 107197 min ago

@ $4.83

Išleistas: 14 vas. 2024 @ 16:35

Grąža: -93.39%

Live Chart Being Loaded With Signals

Commentary (4 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	2.48M
Vidutinė apimtis	959 835
Rinkos kapitalizacija	34.47M
EPS	$0 ( 2024-03-25 )
Kita pelno data	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.390
ATR14	$0.00600 (1.80%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Gu Ehong	Sell	1 731	Ordinary Shares
2024-04-09	Gu Ehong	Sell	17 889	Ordinary Shares
2024-02-15	Poukalov Konstantin	Buy	36 300	Ordinary Shares
2024-02-15	Poukalov Konstantin	Sell	19 218	Ordinary Shares
2024-02-15	Poukalov Konstantin	Sell	36 300	Stock Option (Right to Buy)

INSIDER POWER
70.87
Last 79 transactions
Buy: 50 859 501 \| Sell: 7 434 951

Tūris Koreliacija

Ilgas: 0.35 (neutral)

Trumpas: 0.36 (neutral)

Signal:(47.977) Neutral

LianBio Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
IPHA	0.872
PRDS	0.853
ORIC	0.841
AMRB	0.836
CHRS	0.811
BGNE	0.801

10 Labiausiai neigiamai susiję koreliacijos
EMBC	-0.83

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

LianBio Koreliacija - Valiuta/Žaliavos

-0.21
( neutral )

-0.56
( weak negative )

0.00
( neutral )

0.64
( weak )

LianBio Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$-1.00M (0.00 %)
EPS:	$-1.020

FY	2022
Pajamos:	$0
Bruto pelnas:	$-1.00M (0.00 %)
EPS:	$-1.020

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.03

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.450

Financial Reports:

No articles found.

LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.